{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:31:52Z","timestamp":1792139512530,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mounting evidence suggests that the tumor microenvironment is profoundly immunosuppressive. Thus, mitigating tumor immunosuppression is crucial for inducing sustained antitumor immunity. Whereas previous studies involved intratumoral injection, we report here an inhalable nanoparticle-immunotherapy system targeting pulmonary antigen presenting cells (APCs) to enhance anticancer immunity against lung metastases. Inhalation of phosphatidylserine coated liposome loaded with STING agonist cyclic guanosine monophosphate\u2013adenosine monophosphate (NP-cGAMP) in mouse models of lung metastases enables rapid distribution of NP-cGAMP to both lungs and subsequent uptake by APCs without causing immunopathology. NP-cGAMP designed for enhanced cytosolic release of cGAMP stimulates STING signaling and type I interferons production in APCs, resulting in the pro-inflammatory tumor microenvironment in multifocal lung metastases. Furthermore, fractionated radiation delivered to one tumor-bearing lung synergizes with inhaled NP-cGAMP, eliciting systemic anticancer immunity, controlling metastases in both lungs, and conferring long-term survival in mice with lung metastases and with repeated tumor challenge.<\/jats:p>","DOI":"10.1038\/s41467-019-13094-5","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T14:51:23Z","timestamp":1573224683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":247,"title":["An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases"],"prefix":"10.1038","volume":"10","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Jeffrey","family":"Petty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-9028","authenticated-orcid":false,"given":"Amyn A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"13094_CR1","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"13094_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"13094_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313\u2013322 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"13094_CR4","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1078-0432.CCR-13-2116","volume":"20","author":"A Marabelle","year":"2014","unstructured":"Marabelle, A., Kohrt, H., Caux, C. & Levy, R. Intratumoral immunization: a new paradigm for cancer therapy. Clin. Cancer Res. 20, 1747\u20131756 (2014).","journal-title":"Clin. Cancer Res."},{"key":"13094_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nri3921","volume":"15","author":"GN Barber","year":"2015","unstructured":"Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760\u2013770 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"13094_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786\u2013791 (2013).","journal-title":"Science"},{"key":"13094_CR7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1126\/science.1229963","volume":"339","author":"J Wu","year":"2013","unstructured":"Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339, 826\u2013830 (2013).","journal-title":"Science"},{"key":"13094_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843\u2013852 (2014).","journal-title":"Immunity"},{"key":"13094_CR9","doi-asserted-by":"publisher","first-page":"eaar1916","DOI":"10.1126\/scitranslmed.aar1916","volume":"10","author":"CG Park","year":"2018","unstructured":"Park, C. G. et al. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci. Transl. Med. 10, eaar1916 (2018).","journal-title":"Sci. Transl. Med."},{"key":"13094_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/0008-5472.CAN-14-3619","volume":"76","author":"JR Baird","year":"2016","unstructured":"Baird, J. R. et al. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res. 76, 50\u201361 (2016).","journal-title":"Cancer Res."},{"key":"13094_CR11","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J. Exp. Med. 208, 2005\u20132016 (2011).","journal-title":"J. Exp. Med."},{"key":"13094_CR12","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989\u20132003 (2011).","journal-title":"J. Exp. Med."},{"key":"13094_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830\u2013842 (2014).","journal-title":"Immunity"},{"key":"13094_CR14","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","volume":"28","author":"JD Brody","year":"2010","unstructured":"Brody, J. D. et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study. J. Clin. Oncol. 28, 4324\u20134332 (2010).","journal-title":"J. Clin. Oncol."},{"key":"13094_CR15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540\u20131554 e1512 (2016).","journal-title":"Cell"},{"key":"13094_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41591-018-0302-5","volume":"25","author":"H Liu","year":"2019","unstructured":"Liu, H. et al. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat. Med. 25, 95\u2013102 (2019).","journal-title":"Nat. Med."},{"key":"13094_CR17","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1080\/21645515.2015.1049779","volume":"11","author":"RH Pierce","year":"2015","unstructured":"Pierce, R. H., Campbell, J. S., Pai, S. I., Brody, J. D. & Kohrt, H. E. In-situ tumor vaccination: bringing the fight to the tumor. Hum. Vaccin Immunother. 11, 1901\u20131909 (2015).","journal-title":"Hum. Vaccin Immunother."},{"key":"13094_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.0105-2896.2010.00903.x","volume":"235","author":"GJ Freeman","year":"2010","unstructured":"Freeman, G. J., Casasnovas, J. M., Umetsu, D. T. & DeKruyff, R. H. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol. Rev. 235, 172\u2013189 (2010).","journal-title":"Immunol. Rev."},{"key":"13094_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nature06329","volume":"450","author":"D Park","year":"2007","unstructured":"Park, D. et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO\/Dock180\/Rac module. Nature 450, 430\u2013434 (2007).","journal-title":"Nature"},{"key":"13094_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2011.10.020","volume":"158","author":"J Li","year":"2012","unstructured":"Li, J., Yang, Y. & Huang, L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control Rel. 158, 108\u2013114 (2012).","journal-title":"J. Control Rel."},{"key":"13094_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.biomaterials.2015.12.018","volume":"82","author":"KM Au","year":"2016","unstructured":"Au, K. M. et al. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: turning a bone antiresorptive agent into an anticancer therapeutic. Biomaterials 82, 178\u2013193 (2016).","journal-title":"Biomaterials"},{"key":"13094_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s002800050965","volume":"44","author":"V Knight","year":"1999","unstructured":"Knight, V., Koshkina, N. V., Waldrep, J. C., Giovanella, B. C. & Gilbert, B. E. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother. Pharm. 44, 177\u2013186 (1999).","journal-title":"Cancer Chemother. Pharm."},{"key":"13094_CR23","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/aps.2017.34","volume":"38","author":"S Mangal","year":"2017","unstructured":"Mangal, S., Gao, W., Li, T. & Zhou, Q. T. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharm. Sin. 38, 782\u2013797 (2017).","journal-title":"Acta Pharm. Sin."},{"key":"13094_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrd1632","volume":"4","author":"VP Torchilin","year":"2005","unstructured":"Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145\u2013160 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"13094_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jconrel.2014.03.043","volume":"183C","author":"L Zhang","year":"2014","unstructured":"Zhang, L., Zhou, H., Belzile, O., Thorpe, P. & Zhao, D. Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice. J. Control Rel. 183C, 114\u2013123 (2014).","journal-title":"J. Control Rel."},{"key":"13094_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2176\/nmc.ra.2016-0071","volume":"57","author":"R Saito","year":"2017","unstructured":"Saito, R. & Tominaga, T. Convection-enhanced delivery of therapeutics for malignant gliomas. Neurol. Med. Chir. (Tokyo) 57, 8\u201316 (2017).","journal-title":"Neurol. Med. Chir. (Tokyo)"},{"key":"13094_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ijc.11108","volume":"105","author":"S Krasnici","year":"2003","unstructured":"Krasnici, S. et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int. J. Cancer 105, 561\u2013567 (2003).","journal-title":"Int. J. Cancer"},{"key":"13094_CR28","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.ccell.2014.11.010","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 938 (2014).","journal-title":"Cancer Cell"},{"key":"13094_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13720","volume":"7","author":"D Laoui","year":"2016","unstructured":"Laoui, D. et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat. Commun. 7, 13720 (2016).","journal-title":"Nat. Commun."},{"key":"13094_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).","journal-title":"Nat. Commun."},{"key":"13094_CR31","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379\u20135388 (2009).","journal-title":"Clin. Cancer Res."},{"key":"13094_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6870","volume":"5","author":"GS Herter-Sprie","year":"2014","unstructured":"Herter-Sprie, G. S. et al. Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. Nat. Commun. 5, 5870 (2014).","journal-title":"Nat. Commun."},{"key":"13094_CR33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc.2016.54","volume":"16","author":"C Engblom","year":"2016","unstructured":"Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447\u2013462 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"13094_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723 e714 (2017).","journal-title":"Cancer Cell"},{"key":"13094_CR35","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","volume":"192","author":"JM den Haan","year":"2000","unstructured":"den Haan, J. M., Lehar, S. M. & Bevan, M. J. CD8(+) but not CD8(\u2212) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685\u20131696 (2000).","journal-title":"J. Exp. Med."},{"key":"13094_CR36","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits, E. A. et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203, 1259\u20131271 (2006).","journal-title":"J. Exp. Med."},{"key":"13094_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1158\/2326-6066.CIR-15-0253","volume":"4","author":"SJ Dovedi","year":"2016","unstructured":"Dovedi, S. J. et al. Antitumor efficacy of radiation plus immunotherapy depends upon dendritic cell activation of effector CD8+ T cells. Cancer Immunol. Res. 4, 621\u2013630 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"13094_CR38","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell, C. B. et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2, 578\u2013588 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"13094_CR39","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","volume":"13","author":"S Chiba","year":"2012","unstructured":"Chiba, S. et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832\u2013842 (2012).","journal-title":"Nat. Immunol."},{"key":"13094_CR40","doi-asserted-by":"publisher","first-page":"6597","DOI":"10.1158\/0008-5472.CAN-13-0875","volume":"73","author":"R Perret","year":"2013","unstructured":"Perret, R. et al. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res. 73, 6597\u20136608 (2013).","journal-title":"Cancer Res."},{"key":"13094_CR41","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.ijrobp.2010.09.034","volume":"81","author":"EL Kachikwu","year":"2011","unstructured":"Kachikwu, E. L. et al. Radiation enhances regulatory T cell representation. Int. J. Radiat. Oncol. Biol. Phys. 81, 1128\u20131135 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"13094_CR42","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.20131556","volume":"211","author":"S Srivastava","year":"2014","unstructured":"Srivastava, S., Koch, M. A., Pepper, M. & Campbell, D. J. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J. Exp. Med. 211, 961\u2013974 (2014).","journal-title":"J. Exp. Med."},{"key":"13094_CR43","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41551-018-0262-6","volume":"2","author":"Y Chao","year":"2018","unstructured":"Chao, Y. et al. Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses. Nat. Biomed. Eng. 2, 611\u2013621 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"13094_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","volume":"14","author":"D Shae","year":"2019","unstructured":"Shae, D. et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat. Nanotechnol. 14, 269\u2013278 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"13094_CR45","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373\u2013377 (2015).","journal-title":"Nature"},{"key":"13094_CR46","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi, A. B. et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol. Res. 3, 345\u2013355 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"13094_CR47","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2017.00613","volume":"8","author":"Q Wu","year":"2017","unstructured":"Wu, Q. et al. Modulating both tumor cell death and innate immunity is essential for improving radiation therapy effectiveness. Front. Immunol. 8, 613 (2017).","journal-title":"Front. Immunol."},{"key":"13094_CR48","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nnano.2017.113","volume":"12","author":"Y Min","year":"2017","unstructured":"Min, Y. et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat. Nanotechnol. 12, 877\u2013882 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"13094_CR49","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","volume":"2","author":"S Demaria","year":"2016","unstructured":"Demaria, S., Coleman, C. N. & Formenti, S. C. Radiotherapy: changing the game in immunotherapy. Trends Cancer 2, 286\u2013294 (2016).","journal-title":"Trends Cancer"},{"key":"13094_CR50","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/cam4.1370","volume":"7","author":"W Xiao","year":"2018","unstructured":"Xiao, W. et al. Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population-based study. Cancer Med. 7, 922\u2013930 (2018).","journal-title":"Cancer Med."},{"key":"13094_CR51","doi-asserted-by":"publisher","first-page":"647684","DOI":"10.1155\/2012\/647684","volume":"2012","author":"F Tas","year":"2012","unstructured":"Tas, F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J. Oncol. 2012, 647684 (2012).","journal-title":"J. Oncol."},{"key":"13094_CR52","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1002\/1097-0142(19810601)47:11<2595::AID-CNCR2820471114>3.0.CO;2-Q","volume":"47","author":"J Crow","year":"1981","unstructured":"Crow, J., Slavin, G. & Kreel, L. Pulmonary metastasis: a pathologic and radiologic study. Cancer 47, 2595\u20132602 (1981).","journal-title":"Cancer"},{"key":"13094_CR53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0022-5223(97)70397-0","volume":"113","author":"U Pastorino","year":"1997","unstructured":"Pastorino, U. et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J. Thorac. Cardiovasc. Surg. 113, 37\u201349 (1997).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"13094_CR54","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","volume":"27","author":"KE Rusthoven","year":"2009","unstructured":"Rusthoven, K. E. et al. Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases. J. Clin. Oncol. 27, 1572\u20131578 (2009).","journal-title":"J. Clin. Oncol."},{"key":"13094_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/srep09874","volume":"5","author":"L Zhang","year":"2015","unstructured":"Zhang, L., Zhang, Z., Mason, R. P., Sarkaria, J. N. & Zhao, D. Convertible MRI contrast: sensing the delivery and release of anti-glioma nano-drugs. Sci. Rep. 5, 9874 (2015).","journal-title":"Sci. Rep."},{"key":"13094_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2015.07.048","volume":"69","author":"XJ Du","year":"2015","unstructured":"Du, X. J. et al. Regulating the surface poly(ethylene glycol) density of polymeric nanoparticles and evaluating its role in drug delivery in vivo. Biomaterials 69, 1\u201311 (2015).","journal-title":"Biomaterials"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13094-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13094-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13094-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T01:57:33Z","timestamp":1671242253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13094-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["13094"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-13094-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"9 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5108"}}